Evaluating whether de-escalating to less toxic neoadjuvant chemotherapy yields equivalent outcomes would require an impractically large randomized trial because baseline cure rates are already extremely high. Following the APT trial's precedent, investigators designed the single-arm CompassHER2 trial powered to test if four cycles of THP achieve a three-year recurrence-free survival benchmark greater than 92%.
In the CompassHER2 analysis, anatomical factors like nodal involvement and T stage did not predict pathologic complete response, with the lone exception of T3 tumors in ER-negative disease. Dr. Nadine Tung highlights that biological factors—such as receptor expression and genomic signatures—drive chemosensitivity much more than anatomical tumor volume, suggesting clinicians should base de-escalation decisions primarily on biological characteristics.
While ER-positive/HER2-positive breast cancer typically yields lower pCR rates (34% overall), the HER2-DX pCR score revealed an absolute 40% difference between low and high/medium scores. Patients with ER-positive tumors and high or medium scores achieved pCR rates of 58% to 61% with four cycles of THP, effectively identifying candidates who can safely forgo multi-agent chemotherapy despite traditionally lower response expectations.
Although clinical guidelines often recommend platinum-based TCHP, emerging evidence from trials like NEOCARP and Helena 06 shows that platinum-free THP yields comparable pathologic complete response rates. Dr. Nadine Tung explains that historically, platinum added minimal benefit over taxanes and dual-HER2 antibodies, making platinum omission an attractive de-escalation strategy for stage 2 patients to avoid unnecessary toxicities like neuropathy.
The DESTINY-Breast11 trial demonstrated superior pCR rates using neoadjuvant T-DXd followed by THP, but Dr. Nadine Tung cautions against treating all patients with maximally intensive therapy. Because two-thirds of ER-negative patients already achieve pCR with just four cycles of THP, universal escalation causes overtreatment. Instead, clinicians should reserve intensive antibody-drug conjugate regimens for patients with high tumor burden or unfavorable biology.